1. Home
  2. CRGX vs CCRN Comparison

CRGX vs CCRN Comparison

Compare CRGX & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • CCRN
  • Stock Information
  • Founded
  • CRGX 2021
  • CCRN 1986
  • Country
  • CRGX United States
  • CCRN United States
  • Employees
  • CRGX N/A
  • CCRN N/A
  • Industry
  • CRGX
  • CCRN Professional Services
  • Sector
  • CRGX
  • CCRN Consumer Discretionary
  • Exchange
  • CRGX Nasdaq
  • CCRN Nasdaq
  • Market Cap
  • CRGX 190.0M
  • CCRN 447.2M
  • IPO Year
  • CRGX 2023
  • CCRN N/A
  • Fundamental
  • Price
  • CRGX $4.46
  • CCRN $13.01
  • Analyst Decision
  • CRGX Hold
  • CCRN Hold
  • Analyst Count
  • CRGX 7
  • CCRN 5
  • Target Price
  • CRGX $4.67
  • CCRN $17.93
  • AVG Volume (30 Days)
  • CRGX 502.9K
  • CCRN 264.4K
  • Earning Date
  • CRGX 08-11-2025
  • CCRN 07-30-2025
  • Dividend Yield
  • CRGX N/A
  • CCRN N/A
  • EPS Growth
  • CRGX N/A
  • CCRN N/A
  • EPS
  • CRGX N/A
  • CCRN N/A
  • Revenue
  • CRGX N/A
  • CCRN $1,258,238,000.00
  • Revenue This Year
  • CRGX $57.81
  • CCRN N/A
  • Revenue Next Year
  • CRGX N/A
  • CCRN $5.69
  • P/E Ratio
  • CRGX N/A
  • CCRN N/A
  • Revenue Growth
  • CRGX N/A
  • CCRN N/A
  • 52 Week Low
  • CRGX $3.00
  • CCRN $9.58
  • 52 Week High
  • CRGX $25.45
  • CCRN $18.50
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 57.89
  • CCRN 42.34
  • Support Level
  • CRGX $4.09
  • CCRN $12.72
  • Resistance Level
  • CRGX $4.51
  • CCRN $13.60
  • Average True Range (ATR)
  • CRGX 0.18
  • CCRN 0.58
  • MACD
  • CRGX 0.00
  • CCRN -0.02
  • Stochastic Oscillator
  • CRGX 77.18
  • CCRN 30.08

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About CCRN Cross Country Healthcare Inc. $0.0001 Par Value

Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.

Share on Social Networks: